Form 8-K - Current report:
SEC Accession No. 0001558370-23-001236
Filing Date
2023-02-14
Accepted
2023-02-14 08:20:23
Documents
14
Period of Report
2023-02-14
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aytu-20230214x8k.htm   iXBRL 8-K 36204
2 EX-99.1 aytu-20230214xex99d1.htm EX-99.1 7278
3 GRAPHIC aytu-20230214xex99d1001.jpg GRAPHIC 6681
  Complete submission text file 0001558370-23-001236.txt   175724

Data Files

Seq Description Document Type Size
4 EX-101.SCH aytu-20230214.xsd EX-101.SCH 3131
5 EX-101.LAB aytu-20230214_lab.xml EX-101.LAB 15903
6 EX-101.PRE aytu-20230214_pre.xml EX-101.PRE 10060
8 EXTRACTED XBRL INSTANCE DOCUMENT aytu-20230214x8k_htm.xml XML 4866
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

IRS No.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 23622764
SIC: 2834 Pharmaceutical Preparations